Evidence map›Paper›PMID 35454088›Full record

ArticleBiomolecules2022

In Silico Analysis of the Antagonist Effect of Enoxaparin on the ApoE4-Amyloid-Beta (A

Jorge Alberto Aguilar-Pineda, Silvana G Paco-Coralla, Camilo Febres-Molina, Pamela L Gamero-Begazo, Pallavi Shrivastava, Karin J Vera-López, Gonzalo Davila-Del-Carpio, Patricia López-C, Badhin Gómez, Christian L Lino Cardenas

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.4field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Jorge Alberto Aguilar-PinedaLaboratory of Genomics and Neurovascular Diseases, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0003-2921-5681
Silvana G Paco-CorallaLaboratory of Genomics and Neurovascular Diseases, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0001-9871-6143
Camilo Febres-MolinaDoctorado en Fisicoquímica Molecular, Facultad de Ciencias Exactas, Universidad Andres Bello, Santiago 8370134, Chile.ORCID 0000-0001-9305-7003
Pamela L Gamero-BegazoCentro de Investigación en Ingeniería Molecular-CIIM, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0001-7277-7925
Pallavi ShrivastavaLaboratory of Genomics and Neurovascular Diseases, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.
Karin J Vera-LópezLaboratory of Genomics and Neurovascular Diseases, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0002-7908-8230
Gonzalo Davila-Del-CarpioLaboratory of Genomics and Neurovascular Diseases, Vicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0001-7842-9286
Patricia López-CVicerrectorado de Investigación, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0001-5853-2833
Badhin GómezCentro de Investigación en Ingeniería Molecular-CIIM, Universidad Católica de Santa María, Urb. San José s/n-Umacollo, Arequipa 04000, Peru.ORCID 0000-0001-6539-1207
Christian L Lino CardenasCardiovascular Research Center, Cardiology Division, Massachusetts General Hospital, Boston, MA 02114, USA.ORCID 0000-0001-5491-4375
Catholic University of Santa María · PEMassachusetts General Hospital · USUniversidad Andrés Bello · CL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Apolipoprotein E4 (ApoE4) is thought to increase the risk of developing Alzheimer's disease. Several studies have shown that ApoE4-Amyloid β (Aβ) interactions can increment amyloid depositions in the brain and that this can be augmented at low pH values. On the other hand, experimental studies in transgenic mouse models have shown that treatment with enoxaparin significantly reduces cortical Aβ levels, as well as decreases the number of activated astrocytes around Aβ plaques. However, the interactions between enoxaparin and the ApoE4-Aβ proteins have been poorly explored. In this work, we combine molecular dynamics simulations, molecular docking, and binding free energy calculations to elucidate the molecular properties of the ApoE4-Aβ interactions and the competitive binding affinity of the enoxaparin on the ApoE4 binding sites. In addition, we investigated the effect of the environmental pH levels on those interactions. Our results showed that under different pH conditions, the closed form of the ApoE4 protein, in which the C-terminal domain folds into the protein, remains stabilized by a network of hydrogen bonds. This closed conformation allowed the generation of six different ApoE4-Aβ interaction sites, which were energetically favorable. Systems at pH5 and 6 showed the highest energetic affinity. The enoxaparin molecule was found to have a strong energetic affinity for ApoE4-interacting sites and thus can neutralize or disrupt ApoE4-Aβ complex formation.

Indexed as

Alzheimer DiseaseApolipoprotein E4Amyloid beta-PeptidesAnimalsApolipoprotein E3EnoxaparinHydrogen-Ion ConcentrationMiceMolecular Docking SimulationPlaque, AmyloidAmyloid beta-PeptidesApolipoprotein E3Apolipoprotein E4Enoxaparinalzheimer diseaseamyloid-βapolipoprotein Eenoxaparinmolecular dynamics

Identifiers

PMID35454088
PMCPMC9027285
OpenAlexW4220914507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.